Literature DB >> 27533851

Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.

Sander Bins1, Anne Lenting1, Samira El Bouazzaoui2, Leni van Doorn1, Esther Oomen-de Hoop1, Ferry Alm Eskens1, Ron Hn van Schaik2, Ron Hj Mathijssen1.   

Abstract

AIM: Sorafenib-treated patients display a substantial variation in the incidence of toxicity. We aimed to investigate the association of genetic polymorphisms with observed toxicity on sorafenib. PATIENTS &
METHODS: We genotyped 114 patients that were treated with sorafenib at the Erasmus MC Cancer Institute, the Netherlands, for SLCO1B1, SLCO1B3, ABCC2, ABCG2, UGT1A1 and UGT1A9.
RESULTS: The UGT1A1 (rs8175347) polymorphism was associated with hyperbilirubinemia and treatment interruption. Polymorphisms in SLCO1B1 (rs2306283, rs4149056) were associated with diarrhea and thrombocytopenia, respectively. None of the investigated polymorphisms was associated with overall or progression-free survival in hepatocellular cancer patients.
CONCLUSION: Polymorphisms in SLCO1B1 and UGT1A1 are associated with several different sorafenib side effects.

Entities:  

Keywords:  drug transporters; hepatocellular carcinoma; pharmacogenetics; renal cell cancer; sorafenib; toxicity

Mesh:

Substances:

Year:  2016        PMID: 27533851     DOI: 10.2217/pgs-2016-0063

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  12 in total

Review 1.  Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.

Authors:  Kazuhiro Yamamoto; Ikuko Yano
Journal:  Med Oncol       Date:  2018-01-04       Impact factor: 3.064

Review 2.  PharmGKB summary: sorafenib pathways.

Authors:  Li Gong; Marilyn M Giacomini; Craig Giacomini; Michael L Maitland; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-06       Impact factor: 2.089

Review 3.  Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.

Authors:  Anne Hulin; Jeanick Stocco; Mohamed Bouattour
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

4.  Gilbert's Syndrome, Bilirubin Level and UGT1A1∗28 Genotype in Men of North-West Region of Russia.

Authors:  Andrei Ivanov; Elena Semenova
Journal:  J Clin Exp Hepatol       Date:  2021-02-04

5.  Genetic Polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and Susceptibility to Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Chinese Population-Based Prospective Case-Control Study.

Authors:  Qin Sun; Hai-Peng Liu; Rui-Juan Zheng; Peng Wang; Zhi-Bin Liu; Wei Sha; He-Ping Xiao
Journal:  Clin Drug Investig       Date:  2017-12       Impact factor: 2.859

6.  Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide.

Authors:  S Bins; L van Doorn; M A Phelps; A A Gibson; S Hu; L Li; A Vasilyeva; G Du; P Hamberg; Falm Eskens; P de Bruijn; A Sparreboom; Rhj Mathijssen; S D Baker
Journal:  Clin Transl Sci       Date:  2017-03-31       Impact factor: 4.689

7.  UGT1A1*28 relationship with abnormal total bilirubin levels in chronic hepatitis C patients: Outcomes from a case-control study.

Authors:  Marcelo Moreira Tavares de Souza; Victor Van Vaisberg; Rodrigo Martins Abreu; Aline Siqueira Ferreira; Camila daSilvaFerreira; Paulo Dominguez Nasser; Helena Scavone Paschoale; Flair José Carrilho; Suzane Kioko Ono
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

Review 8.  Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.

Authors:  Elena De Mattia; Erika Cecchin; Michela Guardascione; Luisa Foltran; Tania Di Raimo; Francesco Angelini; Mario D'Andrea; Giuseppe Toffoli
Journal:  World J Gastroenterol       Date:  2019-08-07       Impact factor: 5.742

Review 9.  Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity.

Authors:  Loraine Kay D Cabral; Claudio Tiribelli; Caecilia H C Sukowati
Journal:  Cancers (Basel)       Date:  2020-06-15       Impact factor: 6.639

10.  Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma.

Authors:  Marcus Wölffer; Florian Battke; Martin Schulze; Magdalena Feldhahn; Lukas Flatz; Peter Martus; Andrea Forschner
Journal:  Cancers (Basel)       Date:  2022-01-08       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.